Immunoglobulin‐like transcript 2 blockade restores antitumor immune responses in glioblastoma

Glioblastoma stands as the most frequent primary brain tumor. Despite the multimodal therapy for glioblastoma patients, the survival rate is very low, highlighting the need for novel therapies that improve patient outcomes. Immune checkpoint blockade strategies are achieving promising results in a m...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenzo‐Herrero, Seila, Sordo‐Bahamonde, Christian, Martínez‐Pérez, Alejandra, Corte‐Torres, Mª. Daniela, Fernández‐Vega, Iván, Solís‐Hernández, Mª. Pilar, González, Segundo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807525/
https://www.ncbi.nlm.nih.gov/pubmed/36082628
http://dx.doi.org/10.1111/cas.15575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807525/
https://www.ncbi.nlm.nih.gov/pubmed/36082628
http://dx.doi.org/10.1111/cas.15575

Ejemplares similares